Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
NGENF NERVGEN PHARMA CORP
1.360
-0.034-2.44%
YOY
Do not show
Hide blank lines
(Q3)2022/09/30(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31
Total revenue
0 0 0 0
Operating revenue
-- 0 -- 0 -- 0 -- 0
Cost of revenue
Gross profit
Operating expense
34.27% 4.92M 128.12% 6.31M 124.39% 5M 14.43% 12.81M
Selling and administrative expenses
3.84% 1.71M 98.96% 2.37M -5.52% 1.4M 18.02% 5.94M
-General and administrative expense
3.84% 1.71M 98.96% 2.37M -5.52% 1.4M 18.02% 5.94M
Research and development costs
58.00% 3.19M 148.05% 3.91M 382.45% 3.6M 11.49% 6.87M
Depreciation amortization depletion
5,581.31% 24.32K 7,914.52% 34.22K 121.26% 947 44.14% 2.05K
-Depreciation and amortization
5,581.31% 24.32K 7,914.52% 34.22K 121.26% 947 44.14% 2.05K
Operating profit
-34.27% -4.92M -128.12% -6.31M -124.39% -5M -14.43% -12.81M
Net non-operating interest income expense
-6,954.81% -450.09K 528.80% 33.53K 270.61% 17.34K 56.04% 29.42K
Non-operating interest income
882.52% 64.51K 528.80% 33.53K 270.61% 17.34K 56.04% 29.42K
Non-operating interest expense
-- 514.6K -- -- -- -- -- --
Other net income (expense)
2,971.58% 1.88M -234.03% -39.01K 188.57% 19.41K 706.31% 55.23K
Gain on sale of security
2,971.58% 1.88M -234.03% -39.01K 188.57% 19.41K 706.31% 55.23K
Income before tax
2.87% -3.5M -131.20% -6.32M -121.04% -4.97M -13.77% -12.73M
Income tax
Net income
2.87% -3.5M -131.20% -6.32M -121.04% -4.97M -13.77% -12.73M
Net income continuous Operations
2.87% -3.5M -131.20% -6.32M -121.04% -4.97M -13.77% -12.73M
Minority interest income
Net income attributable to the parent company
2.87% -3.5M -131.20% -6.32M -121.04% -4.97M -13.77% -12.73M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
2.87% -3.5M -131.20% -6.32M -121.04% -4.97M -13.77% -12.73M
Basic earnings per share
33.33% -0.06 -85.71% -0.13 -83.33% -0.11 8.57% -0.32
Diluted earnings per share
33.33% -0.06 -85.71% -0.13 -83.33% -0.11 8.57% -0.32
Dividend per share
Currency Unit
CADCADCADCAD
Audit Opinions
------Unqualified Opinion

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
NervGen Pharma Corp. operates as a regenerative medicine company engaged in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University in Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was founded by Brian J. McAlister and William Joseph Radvakon January 19, 2017 and is headquartered in Vancouver, Canada.
CEO: Mr. Paul Brennan
Market: Pink Market
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist